Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study
- Krzysztof Selmaj
- , David K.B. Li
- , Hans Peter Hartung
- , Bernhard Hemmer
- , Ludwig Kappos
- , Mark S. Freedman
- , Olaf Stüve
- , Peter Rieckmann
- , Xavier Montalban
- , Tjalf Ziemssen
- , Lixin Zhang Auberson
- , Harald Pohlmann
- , Francois Mercier
- , Frank Dahlke
- , Erik Wallström
- Medical University of Lodz
- University of British Columbia
- Heinrich-Heine-University
- University Hospital Basel
- University of Ottawa
- UT Southwestern Medical Center
- VA North Texas Health Care Systems
- Sozialstiftung Bamberg Hospital
- Hospital Universitari Vall d'Hebron
- Technische Universität Dresden
- Novartis Pharma AG
Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung
229
Zitate
(Scopus)